nodes	percent_of_prediction	percent_of_DWPC	metapath
Mifepristone—NR3C1—Clobetasol propionate—psoriasis	0.101	0.121	CbGbCtD
Mifepristone—NR3C1—Fluocinolone Acetonide—psoriasis	0.0762	0.0918	CbGbCtD
Mifepristone—NR3C1—Fluocinonide—psoriasis	0.0762	0.0918	CbGbCtD
Mifepristone—NR3C1—Beclomethasone—psoriasis	0.0762	0.0918	CbGbCtD
Mifepristone—PGR—Betamethasone—psoriasis	0.0509	0.0614	CbGbCtD
Mifepristone—NR3C1—Triamcinolone—psoriasis	0.0303	0.0366	CbGbCtD
Mifepristone—PGR—Dexamethasone—psoriasis	0.0296	0.0357	CbGbCtD
Mifepristone—CYP3A5—Beclomethasone—psoriasis	0.0273	0.0329	CbGbCtD
Mifepristone—NR3C1—Betamethasone—psoriasis	0.026	0.0314	CbGbCtD
Mifepristone—NR3C1—Prednisolone—psoriasis	0.0257	0.0309	CbGbCtD
Mifepristone—NR3C1—Hydrocortisone—psoriasis	0.0243	0.0293	CbGbCtD
Mifepristone—NR3C1—Prednisone—psoriasis	0.0242	0.0292	CbGbCtD
Mifepristone—ABCC1—Cyclosporine—psoriasis	0.0222	0.0267	CbGbCtD
Mifepristone—NR3C1—Dexamethasone—psoriasis	0.0151	0.0182	CbGbCtD
Mifepristone—CYP2D6—Hydroxyurea—psoriasis	0.0127	0.0153	CbGbCtD
Mifepristone—ABCC1—Methotrexate—psoriasis	0.0117	0.0141	CbGbCtD
Mifepristone—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0116	0.014	CbGbCtD
Mifepristone—CYP3A7—Hydrocortisone—psoriasis	0.0116	0.014	CbGbCtD
Mifepristone—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.011	0.0132	CbGbCtD
Mifepristone—CYP3A7—Cyclosporine—psoriasis	0.011	0.0132	CbGbCtD
Mifepristone—CYP3A5—Mycophenolate mofetil—psoriasis	0.0109	0.0131	CbGbCtD
Mifepristone—CYP3A4—Calcitriol—psoriasis	0.00947	0.0114	CbGbCtD
Mifepristone—CYP3A5—Hydrocortisone—psoriasis	0.00871	0.0105	CbGbCtD
Mifepristone—CYP3A5—Cyclosporine—psoriasis	0.00822	0.00991	CbGbCtD
Mifepristone—CYP2D6—Cholecalciferol—psoriasis	0.00767	0.00925	CbGbCtD
Mifepristone—CYP3A4—Methoxsalen—psoriasis	0.00737	0.00888	CbGbCtD
Mifepristone—CYP3A7—Dexamethasone—psoriasis	0.00722	0.0087	CbGbCtD
Mifepristone—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00722	0.0087	CbGbCtD
Mifepristone—ABCB1—Mycophenolate mofetil—psoriasis	0.00706	0.00851	CbGbCtD
Mifepristone—ABCB1—Betamethasone—psoriasis	0.00606	0.0073	CbGbCtD
Mifepristone—ABCB1—Prednisolone—psoriasis	0.00598	0.00721	CbGbCtD
Mifepristone—ABCB1—Hydrocortisone—psoriasis	0.00567	0.00683	CbGbCtD
Mifepristone—ABCB1—Prednisone—psoriasis	0.00565	0.0068	CbGbCtD
Mifepristone—CYP3A5—Dexamethasone—psoriasis	0.00542	0.00653	CbGbCtD
Mifepristone—ABCB1—Cyclosporine—psoriasis	0.00535	0.00645	CbGbCtD
Mifepristone—CYP2D6—Cyclosporine—psoriasis	0.00504	0.00608	CbGbCtD
Mifepristone—CYP3A4—Cholecalciferol—psoriasis	0.00488	0.00588	CbGbCtD
Mifepristone—CYP3A4—Mycophenolate mofetil—psoriasis	0.00423	0.0051	CbGbCtD
Mifepristone—CYP3A4—Triamcinolone—psoriasis	0.00423	0.0051	CbGbCtD
Mifepristone—CYP3A4—Betamethasone—psoriasis	0.00363	0.00438	CbGbCtD
Mifepristone—CYP3A4—Prednisolone—psoriasis	0.00358	0.00432	CbGbCtD
Mifepristone—ABCB1—Dexamethasone—psoriasis	0.00352	0.00425	CbGbCtD
Mifepristone—CYP3A4—Hydrocortisone—psoriasis	0.0034	0.00409	CbGbCtD
Mifepristone—CYP3A4—Prednisone—psoriasis	0.00338	0.00408	CbGbCtD
Mifepristone—CYP2D6—Dexamethasone—psoriasis	0.00332	0.004	CbGbCtD
Mifepristone—CYP3A4—Cyclosporine—psoriasis	0.00321	0.00387	CbGbCtD
Mifepristone—ABCB1—Methotrexate—psoriasis	0.00283	0.00341	CbGbCtD
Mifepristone—CYP3A4—Dexamethasone—psoriasis	0.00211	0.00255	CbGbCtD
Mifepristone—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000971	0.031	CbGpPWpGaD
Mifepristone—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000691	0.022	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—IL22—psoriasis	0.000588	0.0187	CbGpPWpGaD
Mifepristone—AR—Coregulation of Androgen receptor activity—ZMIZ1—psoriasis	0.000559	0.0178	CbGpPWpGaD
Mifepristone—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000558	0.0178	CbGpPWpGaD
Mifepristone—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000551	0.0176	CbGpPWpGaD
Mifepristone—PGR—Ovarian Infertility Genes—VDR—psoriasis	0.000473	0.0151	CbGpPWpGaD
Mifepristone—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000452	0.0144	CbGpPWpGaD
Mifepristone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000452	0.0144	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—ZMIZ1—psoriasis	0.000413	0.0132	CbGpPWpGaD
Mifepristone—PGR—Nuclear Receptors—VDR—psoriasis	0.000412	0.0131	CbGpPWpGaD
Mifepristone—AR—Regulation of Androgen receptor activity—REL—psoriasis	0.000409	0.013	CbGpPWpGaD
Mifepristone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CARM1—psoriasis	0.000407	0.013	CbGpPWpGaD
Mifepristone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000403	0.0129	CbGpPWpGaD
Mifepristone—AR—Regulation of Androgen receptor activity—CARM1—psoriasis	0.000403	0.0128	CbGpPWpGaD
Mifepristone—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000398	0.0127	CbGpPWpGaD
Mifepristone—AR—Coregulation of Androgen receptor activity—CARM1—psoriasis	0.00036	0.0115	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.000337	0.0108	CbGpPWpGaD
Mifepristone—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000327	0.0104	CbGpPWpGaD
Mifepristone—PGR—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000326	0.0104	CbGpPWpGaD
Mifepristone—AR—Nuclear Receptors—VDR—psoriasis	0.000314	0.01	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of Androgen receptor activity—REL—psoriasis	0.00031	0.00989	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of Androgen receptor activity—CARM1—psoriasis	0.000306	0.00974	CbGpPWpGaD
Mifepristone—NR3C1—Circadian Clock—CARM1—psoriasis	0.000297	0.00946	CbGpPWpGaD
Mifepristone—NR3C1—Transcription factor regulation in adipogenesis—LEP—psoriasis	0.000295	0.00941	CbGpPWpGaD
Mifepristone—PGR—Nuclear Receptors—PPARG—psoriasis	0.000287	0.00915	CbGpPWpGaD
Mifepristone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000287	0.00914	CbGpPWpGaD
Mifepristone—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000283	0.00902	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000271	0.00862	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—CARM1—psoriasis	0.000266	0.00848	CbGpPWpGaD
Mifepristone—NR3C1—Transcription factor regulation in adipogenesis—PPARG—psoriasis	0.000257	0.00819	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.000256	0.00816	CbGpPWpGaD
Mifepristone—AR—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000248	0.00791	CbGpPWpGaD
Mifepristone—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000243	0.00776	CbGpPWpGaD
Mifepristone—PGR—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	0.000241	0.00768	CbGpPWpGaD
Mifepristone—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.00024	0.00766	CbGpPWpGaD
Mifepristone—NR3C1—Nuclear Receptors—VDR—psoriasis	0.000238	0.00759	CbGpPWpGaD
Mifepristone—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000237	0.00755	CbGpPWpGaD
Mifepristone—PGR—Cellular roles of Anthrax toxin—TNF—psoriasis	0.000236	0.00753	CbGpPWpGaD
Mifepristone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000233	0.00741	CbGpPWpGaD
Mifepristone—PGR—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000227	0.00723	CbGpPWpGaD
Mifepristone—AR—Nuclear Receptors—PPARG—psoriasis	0.000219	0.00697	CbGpPWpGaD
Mifepristone—ABCC1—S1P1 pathway—VEGFA—psoriasis	0.000202	0.00645	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—IL13—psoriasis	0.0002	0.00638	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.0002	0.00637	CbGpPWpGaD
Mifepristone—NR3C1—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000188	0.006	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000188	0.00599	CbGpPWpGaD
Mifepristone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000188	0.00598	CbGpPWpGaD
Mifepristone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000185	0.0059	CbGpPWpGaD
Mifepristone—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000174	0.00554	CbGpPWpGaD
Mifepristone—AR—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000173	0.00551	CbGpPWpGaD
Mifepristone—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000171	0.00546	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	0.000171	0.00546	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	0.000167	0.00531	CbGpPWpGaD
Mifepristone—NR3C1—Nuclear Receptors—PPARG—psoriasis	0.000166	0.00529	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—IL13—psoriasis	0.000158	0.00503	CbGpPWpGaD
Mifepristone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000152	0.00485	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000152	0.00483	CbGpPWpGaD
Mifepristone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00015	0.00478	CbGpPWpGaD
Mifepristone—AR—Notch-mediated HES/HEY network—CD4—psoriasis	0.000146	0.00466	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000144	0.0046	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—TARS—psoriasis	0.000144	0.00459	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—IL10—psoriasis	0.000142	0.00453	CbGpPWpGaD
Mifepristone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00014	0.00446	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—IL4—psoriasis	0.000138	0.00441	CbGpPWpGaD
Mifepristone—AR—FOXA1 transcription factor network—JUN—psoriasis	0.000138	0.0044	CbGpPWpGaD
Mifepristone—NR3C1—Transcription factor regulation in adipogenesis—TNF—psoriasis	0.000137	0.00435	CbGpPWpGaD
Mifepristone—PGR—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	0.000134	0.00428	CbGpPWpGaD
Mifepristone—NR3C1—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000131	0.00418	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	0.00013	0.00414	CbGpPWpGaD
Mifepristone—Myalgia—Triamcinolone—psoriasis	0.00013	0.000933	CcSEcCtD
Mifepristone—Nervous system disorder—Hydrocortisone—psoriasis	0.000129	0.000931	CcSEcCtD
Mifepristone—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000129	0.000929	CcSEcCtD
Mifepristone—Decreased appetite—Cyclosporine—psoriasis	0.000129	0.000929	CcSEcCtD
Mifepristone—Somnolence—Mycophenolate mofetil—psoriasis	0.000129	0.000927	CcSEcCtD
Mifepristone—Infestation—Methotrexate—psoriasis	0.000129	0.000926	CcSEcCtD
Mifepristone—Infestation NOS—Methotrexate—psoriasis	0.000129	0.000926	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000128	0.000922	CcSEcCtD
Mifepristone—Skin disorder—Hydrocortisone—psoriasis	0.000128	0.000922	CcSEcCtD
Mifepristone—Ill-defined disorder—Betamethasone—psoriasis	0.000128	0.000922	CcSEcCtD
Mifepristone—Ill-defined disorder—Dexamethasone—psoriasis	0.000128	0.000922	CcSEcCtD
Mifepristone—Discomfort—Triamcinolone—psoriasis	0.000128	0.000921	CcSEcCtD
Mifepristone—Fatigue—Cyclosporine—psoriasis	0.000128	0.000921	CcSEcCtD
Mifepristone—Pain—Cyclosporine—psoriasis	0.000127	0.000914	CcSEcCtD
Mifepristone—Constipation—Cyclosporine—psoriasis	0.000127	0.000914	CcSEcCtD
Mifepristone—Dry mouth—Triamcinolone—psoriasis	0.000127	0.000912	CcSEcCtD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	0.000126	0.00403	CbGpPWpGaD
Mifepristone—Angioedema—Betamethasone—psoriasis	0.000126	0.000908	CcSEcCtD
Mifepristone—Angioedema—Dexamethasone—psoriasis	0.000126	0.000908	CcSEcCtD
Mifepristone—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000126	0.000906	CcSEcCtD
Mifepristone—Anorexia—Hydrocortisone—psoriasis	0.000126	0.000905	CcSEcCtD
Mifepristone—Diarrhoea—Mycophenolic acid—psoriasis	0.000126	0.000904	CcSEcCtD
Mifepristone—Angiopathy—Prednisone—psoriasis	0.000125	0.000902	CcSEcCtD
Mifepristone—NR3C1—AP-1 transcription factor network—HLA-A—psoriasis	0.000125	0.00399	CbGpPWpGaD
Mifepristone—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000125	0.0009	CcSEcCtD
Mifepristone—Malaise—Dexamethasone—psoriasis	0.000125	0.000896	CcSEcCtD
Mifepristone—Malaise—Betamethasone—psoriasis	0.000125	0.000896	CcSEcCtD
Mifepristone—Oedema—Triamcinolone—psoriasis	0.000124	0.000894	CcSEcCtD
Mifepristone—Constipation—Mycophenolate mofetil—psoriasis	0.000124	0.000891	CcSEcCtD
Mifepristone—Pain—Mycophenolate mofetil—psoriasis	0.000124	0.000891	CcSEcCtD
Mifepristone—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000124	0.00394	CbGpPWpGaD
Mifepristone—Infection—Triamcinolone—psoriasis	0.000123	0.000888	CcSEcCtD
Mifepristone—Hypotension—Hydrocortisone—psoriasis	0.000123	0.000887	CcSEcCtD
Mifepristone—Feeling abnormal—Cyclosporine—psoriasis	0.000122	0.00088	CcSEcCtD
Mifepristone—Insomnia—Prednisolone—psoriasis	0.000122	0.000879	CcSEcCtD
Mifepristone—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000122	0.00388	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—IL4—psoriasis	0.000122	0.00388	CbGpPWpGaD
Mifepristone—Gastrointestinal pain—Cyclosporine—psoriasis	0.000121	0.000874	CcSEcCtD
Mifepristone—Dizziness—Mycophenolic acid—psoriasis	0.000121	0.000873	CcSEcCtD
Mifepristone—Mental disorder—Prednisone—psoriasis	0.000121	0.000871	CcSEcCtD
Mifepristone—Malnutrition—Prednisone—psoriasis	0.00012	0.000866	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.00012	0.000865	CcSEcCtD
Mifepristone—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.00012	0.00382	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—IL13—psoriasis	0.00012	0.00381	CbGpPWpGaD
Mifepristone—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000119	0.000859	CcSEcCtD
Mifepristone—Insomnia—Hydrocortisone—psoriasis	0.000119	0.000859	CcSEcCtD
Mifepristone—Hypertension—Betamethasone—psoriasis	0.000119	0.000858	CcSEcCtD
Mifepristone—Hypertension—Dexamethasone—psoriasis	0.000119	0.000858	CcSEcCtD
Mifepristone—AR—Regulation of Androgen receptor activity—JUN—psoriasis	0.000119	0.00379	CbGpPWpGaD
Mifepristone—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000118	0.000852	CcSEcCtD
Mifepristone—Urticaria—Cyclosporine—psoriasis	0.000118	0.000849	CcSEcCtD
Mifepristone—Myalgia—Dexamethasone—psoriasis	0.000118	0.000846	CcSEcCtD
Mifepristone—Myalgia—Betamethasone—psoriasis	0.000118	0.000846	CcSEcCtD
Mifepristone—Body temperature increased—Cyclosporine—psoriasis	0.000117	0.000845	CcSEcCtD
Mifepristone—Abdominal pain—Cyclosporine—psoriasis	0.000117	0.000845	CcSEcCtD
Mifepristone—Anxiety—Betamethasone—psoriasis	0.000117	0.000843	CcSEcCtD
Mifepristone—Anxiety—Dexamethasone—psoriasis	0.000117	0.000843	CcSEcCtD
Mifepristone—Vomiting—Mycophenolic acid—psoriasis	0.000117	0.00084	CcSEcCtD
Mifepristone—Discomfort—Dexamethasone—psoriasis	0.000116	0.000836	CcSEcCtD
Mifepristone—Discomfort—Betamethasone—psoriasis	0.000116	0.000836	CcSEcCtD
Mifepristone—Haemoglobin—Methotrexate—psoriasis	0.000116	0.000835	CcSEcCtD
Mifepristone—Rash—Mycophenolic acid—psoriasis	0.000116	0.000833	CcSEcCtD
Mifepristone—Dermatitis—Mycophenolic acid—psoriasis	0.000116	0.000832	CcSEcCtD
Mifepristone—Pain—Prednisolone—psoriasis	0.000116	0.000831	CcSEcCtD
Mifepristone—Haemorrhage—Methotrexate—psoriasis	0.000116	0.000831	CcSEcCtD
Mifepristone—Urticaria—Mycophenolate mofetil—psoriasis	0.000115	0.000828	CcSEcCtD
Mifepristone—Headache—Mycophenolic acid—psoriasis	0.000115	0.000827	CcSEcCtD
Mifepristone—Decreased appetite—Hydrocortisone—psoriasis	0.000115	0.000825	CcSEcCtD
Mifepristone—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000115	0.000824	CcSEcCtD
Mifepristone—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000115	0.000824	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000114	0.00082	CcSEcCtD
Mifepristone—Fatigue—Hydrocortisone—psoriasis	0.000114	0.000819	CcSEcCtD
Mifepristone—AR—Notch-mediated HES/HEY network—STAT3—psoriasis	0.000113	0.00361	CbGpPWpGaD
Mifepristone—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000113	0.000815	CcSEcCtD
Mifepristone—Pain—Hydrocortisone—psoriasis	0.000113	0.000812	CcSEcCtD
Mifepristone—Oedema—Dexamethasone—psoriasis	0.000113	0.000811	CcSEcCtD
Mifepristone—Oedema—Betamethasone—psoriasis	0.000113	0.000811	CcSEcCtD
Mifepristone—Insomnia—Triamcinolone—psoriasis	0.000112	0.000809	CcSEcCtD
Mifepristone—Infection—Dexamethasone—psoriasis	0.000112	0.000806	CcSEcCtD
Mifepristone—Infection—Betamethasone—psoriasis	0.000112	0.000806	CcSEcCtD
Mifepristone—Ill-defined disorder—Prednisone—psoriasis	0.000112	0.000803	CcSEcCtD
Mifepristone—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000111	0.00355	CbGpPWpGaD
Mifepristone—Feeling abnormal—Prednisolone—psoriasis	0.000111	0.000801	CcSEcCtD
Mifepristone—Dyspnoea—Triamcinolone—psoriasis	0.000111	0.000797	CcSEcCtD
Mifepristone—ABCB1—Allograft Rejection—IL13—psoriasis	0.000111	0.00353	CbGpPWpGaD
Mifepristone—Nervous system disorder—Dexamethasone—psoriasis	0.000111	0.000796	CcSEcCtD
Mifepristone—Nervous system disorder—Betamethasone—psoriasis	0.000111	0.000796	CcSEcCtD
Mifepristone—NR3C1—Transcription factor regulation in adipogenesis—IL6—psoriasis	0.00011	0.00351	CbGpPWpGaD
Mifepristone—Angioedema—Prednisone—psoriasis	0.00011	0.000791	CcSEcCtD
Mifepristone—AR—Gene Expression—TARS—psoriasis	0.00011	0.0035	CbGpPWpGaD
Mifepristone—Hypersensitivity—Cyclosporine—psoriasis	0.000109	0.000787	CcSEcCtD
Mifepristone—Nausea—Mycophenolic acid—psoriasis	0.000109	0.000784	CcSEcCtD
Mifepristone—Feeling abnormal—Hydrocortisone—psoriasis	0.000109	0.000782	CcSEcCtD
Mifepristone—Malaise—Prednisone—psoriasis	0.000108	0.000781	CcSEcCtD
Mifepristone—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000108	0.000776	CcSEcCtD
Mifepristone—Anorexia—Dexamethasone—psoriasis	0.000107	0.000773	CcSEcCtD
Mifepristone—Anorexia—Betamethasone—psoriasis	0.000107	0.000773	CcSEcCtD
Mifepristone—Urticaria—Prednisolone—psoriasis	0.000107	0.000772	CcSEcCtD
Mifepristone—Fatigue—Triamcinolone—psoriasis	0.000107	0.000771	CcSEcCtD
Mifepristone—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000107	0.000768	CcSEcCtD
Mifepristone—Asthenia—Cyclosporine—psoriasis	0.000107	0.000767	CcSEcCtD
Mifepristone—Pain—Triamcinolone—psoriasis	0.000106	0.000765	CcSEcCtD
Mifepristone—Hypotension—Betamethasone—psoriasis	0.000105	0.000758	CcSEcCtD
Mifepristone—Hypotension—Dexamethasone—psoriasis	0.000105	0.000758	CcSEcCtD
Mifepristone—Pruritus—Cyclosporine—psoriasis	0.000105	0.000756	CcSEcCtD
Mifepristone—Urticaria—Hydrocortisone—psoriasis	0.000105	0.000754	CcSEcCtD
Mifepristone—Angiopathy—Methotrexate—psoriasis	0.000105	0.000754	CcSEcCtD
Mifepristone—Abdominal pain—Hydrocortisone—psoriasis	0.000104	0.000751	CcSEcCtD
Mifepristone—Body temperature increased—Hydrocortisone—psoriasis	0.000104	0.000751	CcSEcCtD
Mifepristone—Mediastinal disorder—Methotrexate—psoriasis	0.000104	0.000749	CcSEcCtD
Mifepristone—Asthenia—Mycophenolate mofetil—psoriasis	0.000104	0.000748	CcSEcCtD
Mifepristone—Hypertension—Prednisone—psoriasis	0.000104	0.000747	CcSEcCtD
Mifepristone—Chills—Methotrexate—psoriasis	0.000104	0.000746	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000103	0.000739	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000103	0.000739	CcSEcCtD
Mifepristone—Pruritus—Mycophenolate mofetil—psoriasis	0.000102	0.000737	CcSEcCtD
Mifepristone—Arthralgia—Prednisone—psoriasis	0.000102	0.000737	CcSEcCtD
Mifepristone—Myalgia—Prednisone—psoriasis	0.000102	0.000737	CcSEcCtD
Mifepristone—Feeling abnormal—Triamcinolone—psoriasis	0.000102	0.000737	CcSEcCtD
Mifepristone—Anxiety—Prednisone—psoriasis	0.000102	0.000734	CcSEcCtD
Mifepristone—Insomnia—Betamethasone—psoriasis	0.000102	0.000734	CcSEcCtD
Mifepristone—Insomnia—Dexamethasone—psoriasis	0.000102	0.000734	CcSEcCtD
Mifepristone—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000102	0.00325	CbGpPWpGaD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000102	0.000732	CcSEcCtD
Mifepristone—Diarrhoea—Cyclosporine—psoriasis	0.000102	0.000731	CcSEcCtD
Mifepristone—Discomfort—Prednisone—psoriasis	0.000101	0.000728	CcSEcCtD
Mifepristone—Mental disorder—Methotrexate—psoriasis	0.000101	0.000728	CcSEcCtD
Mifepristone—Malnutrition—Methotrexate—psoriasis	0.000101	0.000723	CcSEcCtD
Mifepristone—Hypersensitivity—Prednisolone—psoriasis	9.96e-05	0.000716	CcSEcCtD
Mifepristone—Diarrhoea—Mycophenolate mofetil—psoriasis	9.91e-05	0.000713	CcSEcCtD
Mifepristone—Urticaria—Triamcinolone—psoriasis	9.87e-05	0.00071	CcSEcCtD
Mifepristone—AR—SIDS Susceptibility Pathways—IL10—psoriasis	9.86e-05	0.00314	CbGpPWpGaD
Mifepristone—Body temperature increased—Triamcinolone—psoriasis	9.82e-05	0.000707	CcSEcCtD
Mifepristone—Dizziness—Cyclosporine—psoriasis	9.82e-05	0.000706	CcSEcCtD
Mifepristone—Oedema—Prednisone—psoriasis	9.82e-05	0.000706	CcSEcCtD
Mifepristone—Decreased appetite—Betamethasone—psoriasis	9.8e-05	0.000705	CcSEcCtD
Mifepristone—Decreased appetite—Dexamethasone—psoriasis	9.8e-05	0.000705	CcSEcCtD
Mifepristone—Infection—Prednisone—psoriasis	9.76e-05	0.000702	CcSEcCtD
Mifepristone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.75e-05	0.00311	CbGpPWpGaD
Mifepristone—Gastrointestinal disorder—Dexamethasone—psoriasis	9.73e-05	0.0007	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Betamethasone—psoriasis	9.73e-05	0.0007	CcSEcCtD
Mifepristone—Back pain—Methotrexate—psoriasis	9.73e-05	0.0007	CcSEcCtD
Mifepristone—Hypersensitivity—Hydrocortisone—psoriasis	9.72e-05	0.0007	CcSEcCtD
Mifepristone—Fatigue—Dexamethasone—psoriasis	9.72e-05	0.000699	CcSEcCtD
Mifepristone—Fatigue—Betamethasone—psoriasis	9.72e-05	0.000699	CcSEcCtD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—ICAM1—psoriasis	9.67e-05	0.00308	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—SOCS1—psoriasis	9.65e-05	0.00308	CbGpPWpGaD
Mifepristone—Pain—Betamethasone—psoriasis	9.64e-05	0.000694	CcSEcCtD
Mifepristone—Pain—Dexamethasone—psoriasis	9.64e-05	0.000694	CcSEcCtD
Mifepristone—Nervous system disorder—Prednisone—psoriasis	9.63e-05	0.000693	CcSEcCtD
Mifepristone—Dizziness—Mycophenolate mofetil—psoriasis	9.58e-05	0.000689	CcSEcCtD
Mifepristone—Skin disorder—Prednisone—psoriasis	9.54e-05	0.000686	CcSEcCtD
Mifepristone—ABCB1—Allograft Rejection—IL12B—psoriasis	9.48e-05	0.00302	CbGpPWpGaD
Mifepristone—Asthenia—Hydrocortisone—psoriasis	9.47e-05	0.000681	CcSEcCtD
Mifepristone—Vomiting—Cyclosporine—psoriasis	9.44e-05	0.000679	CcSEcCtD
Mifepristone—PGR—Generic Transcription Pathway—CARM1—psoriasis	9.42e-05	0.003	CbGpPWpGaD
Mifepristone—Rash—Cyclosporine—psoriasis	9.36e-05	0.000674	CcSEcCtD
Mifepristone—Anorexia—Prednisone—psoriasis	9.36e-05	0.000673	CcSEcCtD
Mifepristone—Dermatitis—Cyclosporine—psoriasis	9.35e-05	0.000673	CcSEcCtD
Mifepristone—Pruritus—Hydrocortisone—psoriasis	9.34e-05	0.000672	CcSEcCtD
Mifepristone—Ill-defined disorder—Methotrexate—psoriasis	9.33e-05	0.000671	CcSEcCtD
Mifepristone—Headache—Cyclosporine—psoriasis	9.3e-05	0.000669	CcSEcCtD
Mifepristone—Feeling abnormal—Dexamethasone—psoriasis	9.29e-05	0.000668	CcSEcCtD
Mifepristone—Feeling abnormal—Betamethasone—psoriasis	9.29e-05	0.000668	CcSEcCtD
Mifepristone—ABCB1—Allograft Rejection—HLA-E—psoriasis	9.25e-05	0.00295	CbGpPWpGaD
Mifepristone—Gastrointestinal pain—Dexamethasone—psoriasis	9.22e-05	0.000663	CcSEcCtD
Mifepristone—Gastrointestinal pain—Betamethasone—psoriasis	9.22e-05	0.000663	CcSEcCtD
Mifepristone—Vomiting—Mycophenolate mofetil—psoriasis	9.21e-05	0.000663	CcSEcCtD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	9.2e-05	0.00293	CbGpPWpGaD
Mifepristone—Hypersensitivity—Triamcinolone—psoriasis	9.16e-05	0.000659	CcSEcCtD
Mifepristone—Rash—Mycophenolate mofetil—psoriasis	9.13e-05	0.000657	CcSEcCtD
Mifepristone—Dermatitis—Mycophenolate mofetil—psoriasis	9.13e-05	0.000657	CcSEcCtD
Mifepristone—Headache—Mycophenolate mofetil—psoriasis	9.07e-05	0.000653	CcSEcCtD
Mifepristone—Malaise—Methotrexate—psoriasis	9.07e-05	0.000652	CcSEcCtD
Mifepristone—Diarrhoea—Hydrocortisone—psoriasis	9.03e-05	0.00065	CcSEcCtD
Mifepristone—NR3C1—Regulation of Androgen receptor activity—JUN—psoriasis	9.02e-05	0.00288	CbGpPWpGaD
Mifepristone—Urticaria—Dexamethasone—psoriasis	8.96e-05	0.000644	CcSEcCtD
Mifepristone—Urticaria—Betamethasone—psoriasis	8.96e-05	0.000644	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Prednisone—psoriasis	8.95e-05	0.000644	CcSEcCtD
Mifepristone—Dizziness—Prednisolone—psoriasis	8.94e-05	0.000643	CcSEcCtD
Mifepristone—Asthenia—Triamcinolone—psoriasis	8.92e-05	0.000641	CcSEcCtD
Mifepristone—Body temperature increased—Dexamethasone—psoriasis	8.91e-05	0.000641	CcSEcCtD
Mifepristone—Abdominal pain—Betamethasone—psoriasis	8.91e-05	0.000641	CcSEcCtD
Mifepristone—Body temperature increased—Betamethasone—psoriasis	8.91e-05	0.000641	CcSEcCtD
Mifepristone—Abdominal pain—Dexamethasone—psoriasis	8.91e-05	0.000641	CcSEcCtD
Mifepristone—Insomnia—Prednisone—psoriasis	8.88e-05	0.000639	CcSEcCtD
Mifepristone—Nausea—Cyclosporine—psoriasis	8.82e-05	0.000635	CcSEcCtD
Mifepristone—Pruritus—Triamcinolone—psoriasis	8.79e-05	0.000633	CcSEcCtD
Mifepristone—Dizziness—Hydrocortisone—psoriasis	8.73e-05	0.000628	CcSEcCtD
Mifepristone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.61e-05	0.00275	CbGpPWpGaD
Mifepristone—Nausea—Mycophenolate mofetil—psoriasis	8.6e-05	0.000619	CcSEcCtD
Mifepristone—Myalgia—Methotrexate—psoriasis	8.56e-05	0.000616	CcSEcCtD
Mifepristone—Arthralgia—Methotrexate—psoriasis	8.56e-05	0.000616	CcSEcCtD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	8.56e-05	0.00273	CbGpPWpGaD
Mifepristone—Decreased appetite—Prednisone—psoriasis	8.54e-05	0.000614	CcSEcCtD
Mifepristone—Rash—Prednisolone—psoriasis	8.52e-05	0.000613	CcSEcCtD
Mifepristone—Dermatitis—Prednisolone—psoriasis	8.51e-05	0.000612	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	8.5e-05	0.000612	CcSEcCtD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	8.47e-05	0.0027	CbGpPWpGaD
Mifepristone—Fatigue—Prednisone—psoriasis	8.47e-05	0.000609	CcSEcCtD
Mifepristone—Headache—Prednisolone—psoriasis	8.47e-05	0.000609	CcSEcCtD
Mifepristone—Discomfort—Methotrexate—psoriasis	8.46e-05	0.000608	CcSEcCtD
Mifepristone—Constipation—Prednisone—psoriasis	8.4e-05	0.000604	CcSEcCtD
Mifepristone—Vomiting—Hydrocortisone—psoriasis	8.39e-05	0.000604	CcSEcCtD
Mifepristone—NR3C1—AP-1 transcription factor network—IFNG—psoriasis	8.35e-05	0.00266	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—TARS—psoriasis	8.33e-05	0.00265	CbGpPWpGaD
Mifepristone—Rash—Hydrocortisone—psoriasis	8.32e-05	0.000599	CcSEcCtD
Mifepristone—Dermatitis—Hydrocortisone—psoriasis	8.31e-05	0.000598	CcSEcCtD
Mifepristone—PGR—Signaling by ERBB4—TYK2—psoriasis	8.3e-05	0.00265	CbGpPWpGaD
Mifepristone—Headache—Hydrocortisone—psoriasis	8.27e-05	0.000595	CcSEcCtD
Mifepristone—Dizziness—Triamcinolone—psoriasis	8.22e-05	0.000591	CcSEcCtD
Mifepristone—Infection—Methotrexate—psoriasis	8.15e-05	0.000587	CcSEcCtD
Mifepristone—Feeling abnormal—Prednisone—psoriasis	8.09e-05	0.000582	CcSEcCtD
Mifepristone—Asthenia—Dexamethasone—psoriasis	8.09e-05	0.000582	CcSEcCtD
Mifepristone—Asthenia—Betamethasone—psoriasis	8.09e-05	0.000582	CcSEcCtD
Mifepristone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.08e-05	0.00257	CbGpPWpGaD
Mifepristone—Nervous system disorder—Methotrexate—psoriasis	8.05e-05	0.000579	CcSEcCtD
Mifepristone—Gastrointestinal pain—Prednisone—psoriasis	8.03e-05	0.000578	CcSEcCtD
Mifepristone—Nausea—Prednisolone—psoriasis	8.03e-05	0.000577	CcSEcCtD
Mifepristone—Pruritus—Betamethasone—psoriasis	7.98e-05	0.000574	CcSEcCtD
Mifepristone—Pruritus—Dexamethasone—psoriasis	7.98e-05	0.000574	CcSEcCtD
Mifepristone—Skin disorder—Methotrexate—psoriasis	7.97e-05	0.000573	CcSEcCtD
Mifepristone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.97e-05	0.00254	CbGpPWpGaD
Mifepristone—Vomiting—Triamcinolone—psoriasis	7.9e-05	0.000568	CcSEcCtD
Mifepristone—AR—Androgen receptor signaling pathway—JUN—psoriasis	7.86e-05	0.0025	CbGpPWpGaD
Mifepristone—Nausea—Hydrocortisone—psoriasis	7.84e-05	0.000564	CcSEcCtD
Mifepristone—Rash—Triamcinolone—psoriasis	7.84e-05	0.000564	CcSEcCtD
Mifepristone—Dermatitis—Triamcinolone—psoriasis	7.83e-05	0.000563	CcSEcCtD
Mifepristone—Anorexia—Methotrexate—psoriasis	7.82e-05	0.000563	CcSEcCtD
Mifepristone—Urticaria—Prednisone—psoriasis	7.8e-05	0.000561	CcSEcCtD
Mifepristone—Headache—Triamcinolone—psoriasis	7.78e-05	0.00056	CcSEcCtD
Mifepristone—NR3C1—AP-1 transcription factor network—CXCL8—psoriasis	7.77e-05	0.00248	CbGpPWpGaD
Mifepristone—Body temperature increased—Prednisone—psoriasis	7.76e-05	0.000558	CcSEcCtD
Mifepristone—Abdominal pain—Prednisone—psoriasis	7.76e-05	0.000558	CcSEcCtD
Mifepristone—Diarrhoea—Dexamethasone—psoriasis	7.71e-05	0.000555	CcSEcCtD
Mifepristone—Diarrhoea—Betamethasone—psoriasis	7.71e-05	0.000555	CcSEcCtD
Mifepristone—Hypotension—Methotrexate—psoriasis	7.67e-05	0.000552	CcSEcCtD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	7.66e-05	0.00244	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.66e-05	0.00244	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—IL10—psoriasis	7.48e-05	0.00239	CbGpPWpGaD
Mifepristone—Musculoskeletal discomfort—Methotrexate—psoriasis	7.48e-05	0.000538	CcSEcCtD
Mifepristone—Dizziness—Betamethasone—psoriasis	7.46e-05	0.000536	CcSEcCtD
Mifepristone—Dizziness—Dexamethasone—psoriasis	7.46e-05	0.000536	CcSEcCtD
Mifepristone—Insomnia—Methotrexate—psoriasis	7.42e-05	0.000534	CcSEcCtD
Mifepristone—Nausea—Triamcinolone—psoriasis	7.38e-05	0.000531	CcSEcCtD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—IFNG—psoriasis	7.36e-05	0.00235	CbGpPWpGaD
Mifepristone—Dyspnoea—Methotrexate—psoriasis	7.32e-05	0.000526	CcSEcCtD
Mifepristone—Somnolence—Methotrexate—psoriasis	7.3e-05	0.000525	CcSEcCtD
Mifepristone—Hypersensitivity—Prednisone—psoriasis	7.23e-05	0.00052	CcSEcCtD
Mifepristone—NR3C1—AP-1 transcription factor network—JUN—psoriasis	7.22e-05	0.0023	CbGpPWpGaD
Mifepristone—AR—Generic Transcription Pathway—CARM1—psoriasis	7.17e-05	0.00229	CbGpPWpGaD
Mifepristone—Vomiting—Betamethasone—psoriasis	7.17e-05	0.000516	CcSEcCtD
Mifepristone—Vomiting—Dexamethasone—psoriasis	7.17e-05	0.000516	CcSEcCtD
Mifepristone—Decreased appetite—Methotrexate—psoriasis	7.13e-05	0.000513	CcSEcCtD
Mifepristone—NR3C1—Adipogenesis—LEP—psoriasis	7.12e-05	0.00227	CbGpPWpGaD
Mifepristone—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	7.12e-05	0.00227	CbGpPWpGaD
Mifepristone—Rash—Betamethasone—psoriasis	7.11e-05	0.000511	CcSEcCtD
Mifepristone—Rash—Dexamethasone—psoriasis	7.11e-05	0.000511	CcSEcCtD
Mifepristone—Dermatitis—Dexamethasone—psoriasis	7.1e-05	0.000511	CcSEcCtD
Mifepristone—Dermatitis—Betamethasone—psoriasis	7.1e-05	0.000511	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Methotrexate—psoriasis	7.08e-05	0.00051	CcSEcCtD
Mifepristone—Fatigue—Methotrexate—psoriasis	7.08e-05	0.000509	CcSEcCtD
Mifepristone—Headache—Betamethasone—psoriasis	7.06e-05	0.000508	CcSEcCtD
Mifepristone—Headache—Dexamethasone—psoriasis	7.06e-05	0.000508	CcSEcCtD
Mifepristone—Asthenia—Prednisone—psoriasis	7.05e-05	0.000507	CcSEcCtD
Mifepristone—Pain—Methotrexate—psoriasis	7.02e-05	0.000505	CcSEcCtD
Mifepristone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.97e-05	0.00222	CbGpPWpGaD
Mifepristone—Pruritus—Prednisone—psoriasis	6.95e-05	0.0005	CcSEcCtD
Mifepristone—ABCB1—Allograft Rejection—IL10—psoriasis	6.93e-05	0.00221	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—psoriasis	6.84e-05	0.00218	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—STAT3—psoriasis	6.8e-05	0.00217	CbGpPWpGaD
Mifepristone—Feeling abnormal—Methotrexate—psoriasis	6.76e-05	0.000487	CcSEcCtD
Mifepristone—ABCB1—Allograft Rejection—IL4—psoriasis	6.74e-05	0.00215	CbGpPWpGaD
Mifepristone—Diarrhoea—Prednisone—psoriasis	6.72e-05	0.000483	CcSEcCtD
Mifepristone—Gastrointestinal pain—Methotrexate—psoriasis	6.71e-05	0.000483	CcSEcCtD
Mifepristone—Nausea—Betamethasone—psoriasis	6.7e-05	0.000482	CcSEcCtD
Mifepristone—Nausea—Dexamethasone—psoriasis	6.7e-05	0.000482	CcSEcCtD
Mifepristone—PGR—Signaling Pathways—HCAR2—psoriasis	6.67e-05	0.00213	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—HLA-B—psoriasis	6.59e-05	0.0021	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	6.58e-05	0.0021	CbGpPWpGaD
Mifepristone—Urticaria—Methotrexate—psoriasis	6.52e-05	0.000469	CcSEcCtD
Mifepristone—Dizziness—Prednisone—psoriasis	6.49e-05	0.000467	CcSEcCtD
Mifepristone—Body temperature increased—Methotrexate—psoriasis	6.49e-05	0.000467	CcSEcCtD
Mifepristone—Abdominal pain—Methotrexate—psoriasis	6.49e-05	0.000467	CcSEcCtD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	6.43e-05	0.00205	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	6.43e-05	0.00205	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—JUN—psoriasis	6.36e-05	0.00203	CbGpPWpGaD
Mifepristone—Vomiting—Prednisone—psoriasis	6.24e-05	0.000449	CcSEcCtD
Mifepristone—NR3C1—Adipogenesis—PPARG—psoriasis	6.21e-05	0.00198	CbGpPWpGaD
Mifepristone—Rash—Prednisone—psoriasis	6.19e-05	0.000445	CcSEcCtD
Mifepristone—Dermatitis—Prednisone—psoriasis	6.19e-05	0.000445	CcSEcCtD
Mifepristone—Headache—Prednisone—psoriasis	6.15e-05	0.000443	CcSEcCtD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.13e-05	0.00196	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—NFKB1—psoriasis	6.13e-05	0.00195	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.11e-05	0.00195	CbGpPWpGaD
Mifepristone—Hypersensitivity—Methotrexate—psoriasis	6.05e-05	0.000435	CcSEcCtD
Mifepristone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.01e-05	0.00191	CbGpPWpGaD
Mifepristone—Asthenia—Methotrexate—psoriasis	5.89e-05	0.000424	CcSEcCtD
Mifepristone—Nausea—Prednisone—psoriasis	5.83e-05	0.00042	CcSEcCtD
Mifepristone—Pruritus—Methotrexate—psoriasis	5.81e-05	0.000418	CcSEcCtD
Mifepristone—PGR—Signaling Pathways—TAGAP—psoriasis	5.79e-05	0.00184	CbGpPWpGaD
Mifepristone—PGR—Generic Transcription Pathway—VDR—psoriasis	5.62e-05	0.00179	CbGpPWpGaD
Mifepristone—Diarrhoea—Methotrexate—psoriasis	5.61e-05	0.000404	CcSEcCtD
Mifepristone—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	5.58e-05	0.00178	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—NDUFA5—psoriasis	5.54e-05	0.00177	CbGpPWpGaD
Mifepristone—NR3C1—Generic Transcription Pathway—CARM1—psoriasis	5.44e-05	0.00173	CbGpPWpGaD
Mifepristone—Dizziness—Methotrexate—psoriasis	5.43e-05	0.00039	CcSEcCtD
Mifepristone—AR—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.39e-05	0.00172	CbGpPWpGaD
Mifepristone—Vomiting—Methotrexate—psoriasis	5.22e-05	0.000375	CcSEcCtD
Mifepristone—Rash—Methotrexate—psoriasis	5.17e-05	0.000372	CcSEcCtD
Mifepristone—Dermatitis—Methotrexate—psoriasis	5.17e-05	0.000372	CcSEcCtD
Mifepristone—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.17e-05	0.00165	CbGpPWpGaD
Mifepristone—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	5.15e-05	0.00164	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—JUN—psoriasis	5.15e-05	0.00164	CbGpPWpGaD
Mifepristone—Headache—Methotrexate—psoriasis	5.14e-05	0.00037	CcSEcCtD
Mifepristone—AR—SIDS Susceptibility Pathways—JUN—psoriasis	5.01e-05	0.0016	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	4.95e-05	0.00158	CbGpPWpGaD
Mifepristone—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	4.91e-05	0.00157	CbGpPWpGaD
Mifepristone—Nausea—Methotrexate—psoriasis	4.87e-05	0.000351	CcSEcCtD
Mifepristone—CYP3A7—Metabolism—NDUFA5—psoriasis	4.83e-05	0.00154	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.83e-05	0.00154	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—TP53—psoriasis	4.77e-05	0.00152	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—CYP2S1—psoriasis	4.71e-05	0.0015	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—CARM1—psoriasis	4.53e-05	0.00145	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	4.5e-05	0.00143	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.38e-05	0.0014	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—IL6—psoriasis	4.36e-05	0.00139	CbGpPWpGaD
Mifepristone—AR—Generic Transcription Pathway—VDR—psoriasis	4.28e-05	0.00137	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	4.26e-05	0.00136	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—TP53—psoriasis	4.2e-05	0.00134	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—CYP2S1—psoriasis	4.11e-05	0.00131	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.1e-05	0.00131	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.09e-05	0.0013	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—IFNG—psoriasis	4.07e-05	0.0013	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.07e-05	0.0013	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—IL6—psoriasis	4.06e-05	0.00129	CbGpPWpGaD
Mifepristone—PGR—Generic Transcription Pathway—PPARG—psoriasis	3.92e-05	0.00125	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—IL6—psoriasis	3.85e-05	0.00123	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—STAT3—psoriasis	3.81e-05	0.00121	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—JUN—psoriasis	3.8e-05	0.00121	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.79e-05	0.00121	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—TNF—psoriasis	3.75e-05	0.0012	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.73e-05	0.00119	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—NFKB1—psoriasis	3.66e-05	0.00117	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.55e-05	0.00113	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—NDUFA5—psoriasis	3.49e-05	0.00111	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—CCL20—psoriasis	3.47e-05	0.0011	CbGpPWpGaD
Mifepristone—AR—Gene Expression—CARM1—psoriasis	3.45e-05	0.0011	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—TP53—psoriasis	3.4e-05	0.00108	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.32e-05	0.00106	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—TNF—psoriasis	3.3e-05	0.00105	CbGpPWpGaD
Mifepristone—NR3C1—Generic Transcription Pathway—VDR—psoriasis	3.25e-05	0.00104	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.19e-05	0.00102	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.12e-05	0.000994	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.08e-05	0.000981	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—IL6—psoriasis	3.03e-05	0.000966	CbGpPWpGaD
Mifepristone—AR—Generic Transcription Pathway—PPARG—psoriasis	2.99e-05	0.000952	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—CYP2S1—psoriasis	2.97e-05	0.000947	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—TNF—psoriasis	2.85e-05	0.000908	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.82e-05	0.000897	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—VDR—psoriasis	2.71e-05	0.000863	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—IL6—psoriasis	2.66e-05	0.000848	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—TNF—psoriasis	2.64e-05	0.000841	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—NDUFA5—psoriasis	2.64e-05	0.00084	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.62e-05	0.000836	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—CARM1—psoriasis	2.62e-05	0.000835	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—NDUFA5—psoriasis	2.48e-05	0.000792	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.47e-05	0.000787	CbGpPWpGaD
Mifepristone—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.45e-05	0.000781	CbGpPWpGaD
Mifepristone—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.34e-05	0.000745	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—CARM1—psoriasis	2.3e-05	0.000733	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—IL6—psoriasis	2.3e-05	0.000733	CbGpPWpGaD
Mifepristone—NR3C1—Generic Transcription Pathway—PPARG—psoriasis	2.27e-05	0.000722	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—CYP2S1—psoriasis	2.24e-05	0.000714	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.15e-05	0.000686	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—CYP2S1—psoriasis	2.11e-05	0.000673	CbGpPWpGaD
Mifepristone—AR—Gene Expression—VDR—psoriasis	2.06e-05	0.000657	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—CARM1—psoriasis	2.01e-05	0.00064	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—SOCS1—psoriasis	1.91e-05	0.000608	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—PPARG—psoriasis	1.89e-05	0.000602	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.74e-05	0.000554	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.67e-05	0.000533	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—NDUFA5—psoriasis	1.62e-05	0.000518	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—VDR—psoriasis	1.56e-05	0.000499	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.52e-05	0.000484	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—CARM1—psoriasis	1.45e-05	0.000462	CbGpPWpGaD
Mifepristone—AR—Gene Expression—PPARG—psoriasis	1.44e-05	0.000458	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—CAT—psoriasis	1.42e-05	0.000451	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—LEP—psoriasis	1.41e-05	0.000449	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—APOE—psoriasis	1.41e-05	0.000449	CbGpPWpGaD
Mifepristone—ABCC1—Disease—HLA-A—psoriasis	1.41e-05	0.000448	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—CYP2S1—psoriasis	1.38e-05	0.00044	CbGpPWpGaD
Mifepristone—ABCC1—Disease—APOE—psoriasis	1.31e-05	0.000419	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—NFKBIA—psoriasis	1.31e-05	0.000418	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.3e-05	0.000415	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—CAT—psoriasis	1.23e-05	0.000393	CbGpPWpGaD
Mifepristone—ABCC1—Disease—NOS2—psoriasis	1.22e-05	0.00039	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.15e-05	0.000366	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—APOE—psoriasis	1.1e-05	0.000351	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—CARM1—psoriasis	1.09e-05	0.000349	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—PPARG—psoriasis	1.09e-05	0.000348	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TYK2—psoriasis	1.08e-05	0.000343	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—CARM1—psoriasis	1.03e-05	0.000329	CbGpPWpGaD
Mifepristone—ABCC1—Disease—TYK2—psoriasis	1e-05	0.000319	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—APOE—psoriasis	9.59e-06	0.000306	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—PPARG—psoriasis	9.58e-06	0.000305	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—CXCL8—psoriasis	9.36e-06	0.000298	CbGpPWpGaD
Mifepristone—ABCC1—Disease—CD4—psoriasis	9.06e-06	0.000289	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—CAT—psoriasis	8.92e-06	0.000284	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—JUN—psoriasis	8.7e-06	0.000277	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—NFKB1—psoriasis	8.38e-06	0.000267	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—PPARG—psoriasis	8.35e-06	0.000266	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—VEGFA—psoriasis	7.6e-06	0.000242	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—STAT3—psoriasis	7.53e-06	0.00024	CbGpPWpGaD
Mifepristone—ABCC1—Disease—STAT3—psoriasis	7.02e-06	0.000224	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—APOE—psoriasis	6.93e-06	0.000221	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—CARM1—psoriasis	6.74e-06	0.000215	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—CAT—psoriasis	6.73e-06	0.000215	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—CAT—psoriasis	6.35e-06	0.000202	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—PPARG—psoriasis	6.04e-06	0.000192	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TP53—psoriasis	5.75e-06	0.000183	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—IL6—psoriasis	5.26e-06	0.000168	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—APOE—psoriasis	5.23e-06	0.000167	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—APOE—psoriasis	4.93e-06	0.000157	CbGpPWpGaD
Mifepristone—ABCC1—Disease—IL6—psoriasis	4.9e-06	0.000156	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—PPARG—psoriasis	4.56e-06	0.000145	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—PPARG—psoriasis	4.29e-06	0.000137	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—CAT—psoriasis	4.15e-06	0.000132	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—APOE—psoriasis	3.22e-06	0.000103	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—PPARG—psoriasis	2.81e-06	8.95e-05	CbGpPWpGaD
